Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
FDA Grants Breakthrough Therapy Designation to Olomorasib
FDA Grants Breakthrough Therapy Designation to Olomorasib With Pembrolizumab for NSCLC
Clene Inc
Clene Inc. announces preclinical data showing CNM-Au8 enhances cellular health in Parkinson’s disease models, supporting further clinical development
Gelteq
Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market
Lupin's
Lupin's Aurangabad-based facility gets two observations from US FDA
Aligos Therapeutics
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
8th AVG and 3rd IMRP 2025 Meeting
Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
Amgen
Amgen to invest $600m in new US science and innovation hub
Recall Alert
Recall Alert: Popular Supplement for Men Swapped for Erectile Dysfunction Drug
FDA Approves Subcutaneous Leqembi for Alzheimer's
The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase.
CapVest
CapVest to buy control of generics giant Stada in €10bn deal
Clopidogrel
Clopidogrel might be better than aspirin for long-term heart disease
SFDA approves rapid biotech test
SFDA approves rapid biotech test for early Alzheimer’s detection
1
2
3
4
5
6
7
8
